Literature DB >> 8036820

Inadequate response to intradermal hepatitis A vaccine.

R J Brindle1, C A Morris, R Berger, J B Kurtz.   

Abstract

To assess the efficacy of the intradermal route of administration of hepatitis A vaccine we conducted a study in hospital laboratory workers. Forty-three volunteers were given three different combinations of intradermal and intramuscular hepatitis A vaccine and compared with 18 controls given intramuscular vaccine only. The geometric mean titres (GMT) after one, two and three intradermal doses of 0.1 ml each were 4.5, 28 and 143 IU l-1 respectively. The GMT after one intramuscular dose in the controls was 163 IU l-1. The results indicate that the response to intradermal hepatitis A vaccine is poor and its use cannot be recommended.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8036820     DOI: 10.1016/0264-410x(94)90303-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

Review 1.  Clinical development of a new inactivated hepatitis A vaccine.

Authors:  E Vidor; B Fritzell; S Plotkin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

Review 2.  Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data.

Authors:  E Vidor; R Dumas; V Porteret; F Bailleux; K Veitch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-06       Impact factor: 3.267

Review 3.  Delivery systems for intradermal vaccination.

Authors:  Y C Kim; C Jarrahian; D Zehrung; S Mitragotri; M R Prausnitz
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 4.  Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis.

Authors:  Jenny L Schnyder; Cornelis A De Pijper; Hannah M Garcia Garrido; Joost G Daams; Abraham Goorhuis; Cornelis Stijnis; Frieder Schaumburg; Martin P Grobusch
Journal:  Travel Med Infect Dis       Date:  2020-09-06       Impact factor: 6.211

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.